Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

SLNO
Soleno Therapeutics, Inc. Common Stock
stock NASDAQ

At Close
Jun 6, 2025 3:59:58 PM EDT
75.52USD+0.399%(+0.30)594,117
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-75.22)0
After-hours
Jun 6, 2025 4:00:30 PM EDT
75.51USD-0.093%(-0.07)3,601
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
04:49PM EST  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to new employees.   GlobeNewswire Inc
Jan 24, 2022
08:03AM EST  Soleno Therapeutics Provides Regulatory Update On DCCR For The Treatment Of Prader-Willi Syndrome   Benzinga
08:00AM EST  Soleno Therapeutics Provides Regulatory Update on DCCR for the   GlobeNewswire Inc
Jan 5, 2022
08:00AM EST  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced thatAnish Bhatnagar, M.D., Chief Executive Officer, will participate in a panel discussion during the LifeSci Partners 11th Annual Corporate Access Event.   GlobeNewswire Inc
Nov 19, 2021
04:05PM EST  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee.   GlobeNewswire Inc
Nov 10, 2021
06:05PM EST  Soleno Therapeutics Q3 EPS $(0.10) Up From $(0.11) YoY   Benzinga
Sep 23, 2021
08:00AM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced thatAnish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference onThursday, September 30, 2021at2:40 PM Eastern Time.   GlobeNewswire Inc
Sep 16, 2021
04:05PM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced thatAnish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit onMonday, September 20, 2021at1:15 PM Eastern Time.   GlobeNewswire Inc
Sep 8, 2021
08:07AM EDT  Soleno Therapeutics Announces Results Showing A 'Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602'; Says On Track For Data Submission To FDA In Q3   Benzinga
08:00AM EDT  Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602   GlobeNewswire Inc
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 4, 2021
05:35AM EDT  Soleno Therapeutics 10+% Owner Jack Schuler Reported Sale of 2,072,347 Shares @ Avg Price of $1.88/Share in Form 4 Filing on Tuesday   Benzinga
Jul 28, 2021
04:50PM EDT  Soleno Therapeutics Q2 EPS $(0.25) Down From $(0.16) YoY   Benzinga
04:49PM EDT  CORRECTION: Soleno Therapeutics Q2 EPS $(0.25) Down From $(0.16) YoY   Benzinga
04:48PM EDT  Soleno Therapeutics Q2 Adj. EPS $0.05 Up From $(0.16) YoY   Benzinga
04:05PM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six months ended June 30, 2021.   GlobeNewswire Inc
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 6, 2021
08:06AM EDT  Soleno Therapeutics Says On Jul. 2 Received Official meeting Minutes From Type B FDA Meeting; FDA Continued To Assert That Based On Data, Additional Trial Is Necessary For NDA But Encouraged Co. To Submit Available Data   Benzinga
08:00AM EDT  Soleno Therapeutics Provides Regulatory Update on DCCR for the   GlobeNewswire Inc
Jun 2, 2021
09:41AM EDT  Soleno Stock Shoots Higher as Diazoxide Choline Gets US Orphan Drug Tag for Glycogen Storage Disease   Benzinga
08:17AM EDT  Soleno Therapeutics Secures Orphan Drug Designation From FDA For Diazoxide Choline   RTTNews
08:01AM EDT  Soleno Therapeutics Receives Orphan Drug Designation From FDA For Diazoxide Choline For Treatment Of Glycogen Storage Disease Type 1a   Benzinga
08:00AM EDT  Soleno Therapeutics Receives Orphan Drug Designation from FDA for   GlobeNewswire Inc
May 21, 2021
08:00AM EDT  Soleno Therapeutics to Host Webinar Highlighting DCCR for   GlobeNewswire Inc
May 20, 2021
08:01AM EDT  Soleno Therapeutics To Participate In Oppenheimer Rare & Orphan Disease Summit May 21 At 1:15 p.m. ET   Benzinga
08:00AM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced thatAnish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 at 1:15 PM Eastern Time.   GlobeNewswire Inc
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 5, 2021
04:33PM EDT  Soleno Therapeutics Q1 EPS $(0.11) Up From $(0.13) YoY   Benzinga
04:01PM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended March 31, 2021.   GlobeNewswire Inc
May 4, 2021
09:16AM EDT  Soleno Therapeutics' DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome Patients   Benzinga
08:07AM EDT  Soleno Therapeutics Announces Presentation Of Behavioral Data From Ongoing Extension Study Of DCCR For Treatment Of Prader-Willi Syndrome; Says 'Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR'   Benzinga
08:00AM EDT  Results Show Improvement in Multiple Behavioral Domains Following Treatment with DCCR   GlobeNewswire Inc
Apr 21, 2021
07:31AM EDT  The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue   Benzinga
Apr 14, 2021
08:40PM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, participated in a Prader-Willi Syndrome (PWS) DCCR Town Hall on Wednesday, April 14, 2021.   GlobeNewswire Inc
Apr 13, 2021
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
Mar 9, 2021
04:01PM EST  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16, 2021 at 1:50 PM Eastern Time.   GlobeNewswire Inc
Mar 8, 2021
02:38PM EST  Mid-Afternoon Market Update: Nasdaq Drops Over 150 Points; Crude Oil Down 2%   Benzinga
12:03PM EST  Mid-Day Market Update: Dow Jumps 500 Points; AnaptysBio Shares Plunge   Benzinga
10:14AM EST  Mid-Morning Market Update: Markets Gain; US Senate Clears $1.9 Trillion Covid-19 Relief Bill   Benzinga
08:53AM EST  Soleno Shares Are Trading Lower After FDA Demands Additional Study For DCCR Program In Prader-Willi Syndrome   Benzinga
08:46AM EST  Soleno Therapeutics Provides Regulatory Update on DCCR for the   GlobeNewswire Inc
08:08AM EST  Soleno Therapeutics Announces FDA Has Inform Co. That An Additional Controlled Trial Will Be Necessary To Support An NDA Submission For DCCR In PWS Following Its Review Of The Data Submitted By The Co.   Benzinga
Mar 3, 2021
04:01PM EST  Soleno Therapeutics Q4 EPS $(0.04) Up From $(0.36) YoY   Benzinga
04:01PM EST  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2020.   GlobeNewswire Inc
Feb 23, 2021
09:38AM EST  Soleno Therapeutics, Vanderbilt University In Research Pact For K(ATP) Channel Activators   Benzinga
08:06AM EST  Soleno Therapeutics Announces Collaboration With Vanderbilt University To Discover And Develop KATP Channel Activators For Treatment Of Rare Diseases; Financial Details Not Disclosed   Benzinga
08:00AM EST  Soleno Therapeutics Announces Collaboration with Vanderbilt   GlobeNewswire Inc
Feb 5, 2021
08:00AM EST  Soleno Therapeutics Provides Recap of Key Opinion Leader Webinar   GlobeNewswire Inc
Jan 28, 2021
08:00AM EST  Soleno Therapeutics to Host Key Opinion Leader Meeting on DCCR for   GlobeNewswire Inc
Jan 14, 2021
05:57PM EST  Soleno Therapeutics S-3 Shows Registration For $100M Mixed Securities Shelf Offering   Benzinga
Jan 4, 2021
08:00AM EST  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced thatmanagement will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.   GlobeNewswire Inc
Dec 11, 2020
08:37AM EST  Soleno Therapeutics Announces Receipt Of Official Meeting Minutes From Type C Meeting With FDA   RTTNews
08:32AM EST  Soleno Therapeutics Announces Receipt Of Type C Meeting Minutes With FDA; Says 'confirmed the discussion with the FDA regarding the potential adequacy of data from completed and ongoing studies with DCCR'   Benzinga
08:30AM EST  Soleno Therapeutics Provides Regulatory Update on DCCR for the   GlobeNewswire Inc
Nov 12, 2020
10:12AM EST  Soleno Therapeutics shares were trading lower after the company reported Q3 EPS results down from last year.   Benzinga
Nov 10, 2020
04:01PM EST  Soleno Therapeutics Q3 EPS $(0.11) Down From $0.03 YoY   Benzinga
04:01PM EST  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter and nine months ended September 30, 2020.   GlobeNewswire Inc
Nov 4, 2020
08:21AM EST  The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings   Benzinga
Nov 3, 2020
04:02PM EST  Soleno Therapeutics Announces Presentation Of Body Composition Results From DESTINY PWS, A Phase III Trial Of DCCR In Prader-Willi Syndrome   Benzinga
04:01PM EST  Soleno Therapeutics Announces Presentation of Body Composition   GlobeNewswire Inc
Oct 29, 2020
08:31AM EDT  Soleno Therapeutics Announces Late-Breaking Oral Presentation With Body Composition Results From Phase III DESTINY PWS Trial Of DCCR In Prader-Willi Syndrome At ObesityWeek 2020 Meeting   Benzinga
08:01AM EDT  Soleno Therapeutics Announces Late-Breaking Oral Presentation with   GlobeNewswire Inc
Sep 30, 2020
02:40PM EDT  Updated Results Demonstrate Significant DCCR Exposure Response Relationship   GlobeNewswire Inc
Sep 29, 2020
07:53AM EDT  Guggenheim Initiates Coverage On Soleno Therapeutics with Buy Rating, Announces Price Target of $8   Benzinga
Sep 15, 2020
08:00AM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced thatAnish Bhatnagar, M.D., Chief Executive Officer, will participate in a fireside chat at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitonMonday, September 21, 2020, at4:10 PM ET.   GlobeNewswire Inc
Aug 10, 2020
04:30PM EDT  Soleno Therapeutics Q2 EPS $(0.16) Up From $(0.31) YoY   Benzinga
04:01PM EDT  Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the second quarter and six months ended June 30, 2020.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC